Next-Generation Sequencing In Metastatic Lung Cancer Patients: Translation From Sequence Data Into Clinical Practice.

e12521 Background: Several patients with lung cancer (LC) maintain good performance status even after disease progression following all standard therapies. More recently, targeted therapies have been improving prognosis of patients with advanced LC. We aim at exploring the role of a next-generation sequencing (NGS) assay in identifying therapeutic targets for refractory LC. Methods: Patients diagnosed with metastatic LC with available paraffin-embedded tissue evaluated by the method of NGS (Foundation Medicine, USA) were included. Hybridization capture of 3,769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to ≥ 50 ng of DNA extracted from 12 LC specimens and sequenced to high, uniform coverage. Genomic alterations (GA) were reported for each patient sample. Actionable GA were defined as those identifying anti-cancer targeted therapies available on the market or in registered clinical trials. Results: Twenty-nine patients were included (86.2% adeno...